Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, announced a strategic partnership with Turbine, a leading virtual biology company, to advance translational oncology research by integrating Turbine’s in silico Virtual Assays with its Tumor Organoid Assays based on HUB Organoid Technology. This collaboration establishes a connected workflow that enables researchers to move more efficiently from hypothesis to validation.

Turbine’s Virtual Assays simulate biological response across thousands of biological samples and hundreds of drugs, generating predictive insights to identify and prioritize targets, therapies, and combinations. The predictions will be enhanced through the incorporation of multimodal and drug response data from hundreds of tumor organoid models at Crown Bioscience. Together, the companies create a closed-loop approach linking prediction with validation, improving predictive accuracy, reducing experimental burden, whilst delivering greater biological relevance and translational confidence.

Guided by Turbine’s in silico predictions, select hypotheses can be experimentally validated using Crown Bioscience’s tumor organoid assays, streamlining experimental design, reducing costs, and shortening development timelines.

This approach enables researchers to generate insights earlier, focus resources on the most promising strategies, and make faster, more informed decisions with greater confidence in clinical translatability.

“Translational success depends on how well early insights reflect real patient biology,” said John Gu, CEO of Crown Bioscience. “By integrating predictive modeling with our organoid models, we are creating a more robust foundation for decision-making, one that improves confidence, reduces risk, and accelerates the path to the clinic.”

“Together with Crown Bioscience, we aim to address a key trade-off in drug discovery between scale and translatability,” said Szabolcs Nagy, CEO of Turbine. “Using our Virtual Lab, researchers can already explore millions of hypotheses in silico. By integrating with Crown’s organoid platform, we enable virtual experimentation that better reflects patient biology, helping close the translatability gap.”